At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)
In Brief
A Phase 2 clinical trial evaluating IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically when immediately followed by the non-specific immune stimulation provided by treatment with HD IL-2 and thereby increase the response rate and complete response for metastatic clear cell renal cell cancer patients. Both HD IL-2 and SABR are FDA approved therapeutic cancer treatment
Study Details
Timeline
Interventions
HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
SABR dose varying from 8Gy-20Gy in 1-3 fractions